JP2024041896A5 - - Google Patents

Download PDF

Info

Publication number
JP2024041896A5
JP2024041896A5 JP2024002472A JP2024002472A JP2024041896A5 JP 2024041896 A5 JP2024041896 A5 JP 2024041896A5 JP 2024002472 A JP2024002472 A JP 2024002472A JP 2024002472 A JP2024002472 A JP 2024002472A JP 2024041896 A5 JP2024041896 A5 JP 2024041896A5
Authority
JP
Japan
Prior art keywords
substituent
present
composition
halogen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024002472A
Other languages
English (en)
Japanese (ja)
Other versions
JP7789402B2 (ja
JP2024041896A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/060101 external-priority patent/WO2019094772A1/en
Application filed filed Critical
Publication of JP2024041896A publication Critical patent/JP2024041896A/ja
Publication of JP2024041896A5 publication Critical patent/JP2024041896A5/ja
Application granted granted Critical
Publication of JP7789402B2 publication Critical patent/JP7789402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024002472A 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法 Active JP7789402B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762584473P 2017-11-10 2017-11-10
US62/584,473 2017-11-10
PCT/US2018/060101 WO2019094772A1 (en) 2017-11-10 2018-11-09 Ash1l degraders and methods of treatment therewith
JP2020526059A JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020526059A Division JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法

Publications (3)

Publication Number Publication Date
JP2024041896A JP2024041896A (ja) 2024-03-27
JP2024041896A5 true JP2024041896A5 (https=) 2024-04-10
JP7789402B2 JP7789402B2 (ja) 2025-12-22

Family

ID=66432988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法
JP2024002472A Active JP7789402B2 (ja) 2017-11-10 2024-01-11 Ash1l分解剤及びそれを用いた治療方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020526059A Active JP7424637B2 (ja) 2017-11-10 2018-11-09 Ash1l分解剤及びそれを用いた治療方法
JP2020526068A Pending JP2021502388A (ja) 2017-11-10 2018-11-09 Ash1l阻害剤及びそれを用いた治療方法

Country Status (6)

Country Link
US (7) US11110177B2 (https=)
EP (2) EP3706737B1 (https=)
JP (3) JP7424637B2 (https=)
CN (2) CN111655257B (https=)
CA (2) CA3082077A1 (https=)
WO (2) WO2019094773A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR102758231B1 (ko) * 2019-06-12 2025-01-23 상하이테크 유니버시티 Alk 단백질 조절제 및 이의 항종양 용도
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
DK4034104T3 (da) * 2019-09-23 2025-10-06 Pmv Pharmaceuticals Inc Metoder og forbindelser til genoprettelse af mutant p53-funktion
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
KR102325607B1 (ko) * 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
AU2021293907A1 (en) * 2020-06-17 2023-01-19 Dana-Farber Cancer Institute, Inc. Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
CN113004251B (zh) * 2021-03-05 2022-09-27 郑州大学第一附属医院 含2-硝基咪唑的喹唑啉类衍生物及其应用
CN115960104A (zh) * 2021-10-09 2023-04-14 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
WO2024080793A1 (en) * 2022-10-13 2024-04-18 Hanmi Pharm. Co., Ltd. Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same
CN121532212A (zh) * 2023-07-04 2026-02-13 西藏海思科制药有限公司 一种抑制并降解irak4的化合物的药物组合物及其在药学上的应用
US20250136824A1 (en) * 2023-11-01 2025-05-01 The Boeing Company Corrosion inhibition coatings with thiirane crosslinkers and methods thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863A (en) 1848-10-17 Matthias p
US5861A (en) 1848-10-17 Locking umbrella and parasol
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US510A (en) 1837-12-07 soeel
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
EP0457803A4 (en) 1989-02-08 1991-12-04 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5391452A (en) 1993-08-02 1995-02-21 Xerox Corporation Polyester toner and developer compositions
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
DK1042287T3 (da) * 1997-12-24 2005-08-15 Aventis Pharma Gmbh Indolderivater som inhibitorer af faktor Xa
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP4505566B2 (ja) * 2004-09-30 2010-07-21 愛知県 肺癌治療剤
US20080233101A1 (en) 2005-09-15 2008-09-25 The Regents Of The University Of California RNA-mediated epigenetic regulation of gene transcription
CA2637933C (en) * 2006-01-24 2013-03-12 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
PT2057139E (pt) 2006-07-18 2013-12-05 Antibe Holdings Inc Derivados de sulfureto de hidrogénio de fármacos antiinflamatórios não esteroidais
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009015067A2 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
RU2537549C2 (ru) * 2008-01-04 2015-01-10 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
CA2823837A1 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
AU2012220620A1 (en) * 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US9889180B2 (en) 2012-11-19 2018-02-13 Agency For Science, Technology And Research Method of treating cancer
DK2970265T3 (en) * 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
EP2968551B1 (en) * 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
CN105940005A (zh) * 2014-01-31 2016-09-14 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3334733A1 (en) * 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2017096045A1 (en) * 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds
US10759808B2 (en) * 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
KR20180132861A (ko) * 2016-04-12 2018-12-12 더 리젠츠 오브 더 유니버시티 오브 미시간 Bet 단백질 분해제
CA3018429A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
ES2910787T3 (es) * 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. Egfrタンパク質分解標的化キメラ分子およびその関連する使用方法
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
JP7123197B2 (ja) 2021-01-06 2022-08-22 エルジー ディスプレイ カンパニー リミテッド 音響発生器及び音響装置

Similar Documents

Publication Publication Date Title
JP2024041896A5 (https=)
JP2024028453A5 (https=)
JP2021502386A5 (https=)
JP2021169499A5 (https=)
JP2023166381A5 (https=)
JP2022078315A5 (https=)
RU2005126418A (ru) Синтез 4-амино-2-бутеноилхлоридов и их использование при получении 3-цианохинолинов
JP2023171659A5 (https=)
JP2004182741A5 (https=)
JP2005509735A5 (https=)
JP2007503388A5 (https=)
JP2011503096A5 (https=)
JPWO2023106310A5 (https=)
JP2023534131A5 (https=)
JP2004536811A5 (https=)
CA2496815A1 (en) Dihydropyridinone derivatives
JP2006502283A5 (https=)
JP2005517643A5 (https=)
JP2006503809A5 (https=)
JP2005538089A5 (https=)
JP2008513432A5 (https=)
JP2023518776A5 (https=)
JP2004190075A5 (https=)
JP2006523241A5 (https=)
JP2023518543A5 (https=)